Concurrent acalabrutinib, bendamustine, and rituximab in the first-line setting improved outcomes for patients with mantle cell lymphoma (MCL) relative to sequential treatment without acalabrutinib.
In chronic myeloid leukemia, combining asciminib with a tyrosine kinase inhibitor shows increasing efficacy and tolerability over 3 years.
Removing etoposide did not negatively affect OS, DFS, MRD, or relapse rate at 3 years for pediatric patients with LR1, LR2 or high-risk AML.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback